LKFT vs SNY
Galapagos NV and Sanofi, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | LKFT | SNY |
|---|---|---|
| Revenue | €1.1B | €43.6B |
| Net income | €320.9M | €7.8B |
| Gross margin | 97.3% | 77.2% |
| Net margin | 28.9% | 17.9% |
| Return on equity | — | 10.5% |
| Diluted EPS | €4.87 | €6.37 |
| Dividend / share | — | €3.92 |
| Payout ratio | — | 61.1% |
| Free cash flow | €-271.2M | — |
| Equity | — | €71.4B |
| Net debt / equity | — | 0.15× |
| Current ratio | 20.15× | 1.09× |
| Revenue CAGR 5y | 18.4% | 3.9% |
| Profit CAGR 5y | — | −8.7% |
SNY bills 39.2× the revenue of LKFT, and LKFT keeps more of each dollar of revenue as profit (28.9% against 17.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | LKFT | SNY |
|---|---|---|
| FY2025 | €1.1B | €43.6B |
| FY2024 | €275.6M | €41.1B |
| FY2023 | €239.7M | €37.8B |
| FY2022 | €241.2M | €37.7B |
| FY2021 | €234.4M | €37.8B |
| FY2020 | €478.1M | €36.0B |
| FY2019 | €834.9M | €36.1B |
| FY2018 | €278.7M | €34.5B |
| FY2017 | €127.1M | €35.1B |
| FY2016 | €129.5M | €33.8B |
Net income by year
Bottom line
| Fiscal year | LKFT | SNY |
|---|---|---|
| FY2025 | €320.9M | €7.8B |
| FY2024 | €74.1M | €5.6B |
| FY2023 | €211.7M | €5.4B |
| FY2022 | €-218.0M | €8.4B |
| FY2021 | €-103.2M | €6.2B |
| FY2020 | €-305.4M | €12.3B |
| FY2019 | €149.8M | €2.8B |
| FY2018 | €-29.3M | €4.3B |
| FY2017 | €-115.7M | €8.4B |
| FY2016 | €54.0M | €4.7B |
Advertisement
AdSense · Rectangle 336×280